Metabolism and disposition in rats, dogs, and humans of erdafitinib, an orally administered potent pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor
Sign Up to like & getrecommendations! Published in 2020 at "Xenobiotica"
DOI: 10.1080/00498254.2020.1821123
Abstract: Abstract This article describes in vivo biotransformation and disposition of erdafitinib following single oral dose of 3H-erdafitinib and 14C-erdafitinib to intact and bile duct-cannulated (BC) rats (4 mg/kg), 3H-erdafitinib to intact dogs (0.25 mg/kg), and 14C-erdafitinib to… read more here.
Keywords: disposition rats; erdafitinib major; metabolism disposition; rats dogs ... See more keywords